↓ Skip to main content

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Overview of attention for article published in Clinical Pharmacology & Therapeutics, May 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
1 news outlet
twitter
2 tweeters
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
250 Dimensions

Readers on

mendeley
190 Mendeley
citeulike
3 CiteULike
Title
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
Published in
Clinical Pharmacology & Therapeutics, May 2012
DOI 10.1038/clpt.2012.57
Pubmed ID
Authors

R A Wilke, L B Ramsey, S G Johnson, W D Maxwell, H L McLeod, D Voora, R M Krauss, D M Roden, Q Feng, R M Cooper-DeHoff, L Gong, T E Klein, M Wadelius, M Niemi

Abstract

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 190 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 8 4%
India 1 <1%
Brazil 1 <1%
Canada 1 <1%
Chile 1 <1%
Unknown 178 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 43 23%
Student > Ph. D. Student 30 16%
Student > Master 22 12%
Other 20 11%
Student > Bachelor 19 10%
Other 40 21%
Unknown 16 8%
Readers by discipline Count As %
Medicine and Dentistry 57 30%
Agricultural and Biological Sciences 40 21%
Pharmacology, Toxicology and Pharmaceutical Science 27 14%
Biochemistry, Genetics and Molecular Biology 21 11%
Immunology and Microbiology 3 2%
Other 18 9%
Unknown 24 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2021.
All research outputs
#1,429,085
of 18,156,586 outputs
Outputs from Clinical Pharmacology & Therapeutics
#216
of 3,717 outputs
Outputs of similar age
#7,592
of 102,173 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#3
of 24 outputs
Altmetric has tracked 18,156,586 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,717 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.